Category Archives: Neurotechnology

Lithuanian biometric software company Neurotechnology has announced the release of two biometric time and attendance tracking products.

The release includes the new NCheck Cloud Bio Attendance cloud-based service and the updated NCheck Bio Attendance 4.0 software.

NCheck Cloud Bio Attendance uses biometric face recognition to enable users to check in and out from anywhere via the internet by taking selfies using personal devices or a dedicated device for all users in the company.

The company noted that NCheck Bio Attendance software provides enhanced speed and usability and adds iris recognition to its fingerprint and face recognition capabilities for mobile or on-site time and attendance logging. Both NCheck Cloud Bio Attendance and NCheck Bio Attendance 4.0 generate reports on their own and can export data to third party payroll applications.

A company can set up the NCheck Cloud time and attendance solution in just a few minutes, said Vaidas Didvalis, NCheck project manager for Neurotechnology. Users can check-in and check-out from anywhere using their own devices or they can use a dedicated device for a group of users. Iris recognition integration into the standalone NCheck Bio Attendance enables biometric check-in and check-out when fingerprints and face cannot be used a capability that hospitals and clinical research labs find particularly useful, Didvalis added.

The company said the new NCheck Cloud Bio Attendance cloud-based time and attendance service, all data is accessible via the internet, so administrators can review attendance data, generate reports, add new users and complete other administrative functions with no need to install or maintain software. Up to five users can be registered using a free account.

NCheck Bio Attendance 4.0 provides an extra measure of security with the addition of RFID card and barcode reader integration, which enables user identification through a combination of card scans and biometric verification. The addition of iris recognition is particularly useful in facilities where users cannot touch fingerprint sensors or where faces are often covered, such as hospitals and laboratories. The system administrator can choose which biometric option is preferred.

The latest NCheck version also includes an array of useful new reports, including productivity, absentee and late arrival. As in previous versions, NCheck Bio Attendance 4.0 works with standard Windows PCs and off-the-shelf Android devices; supports a wide range of fingerprint scanners, device cameras and webcams; and includes GPS logging, database synchronization for remote workers, user grouping, shift support and attendance planning among other capabilities.

View original post here:

Neurotechnology releases new biometric access solutions - Planet Biometrics

March 28, 2017-

Neurotechnology has released two biometric time and attendance tracking products including the new NCheck Cloud Bio Attendance cloud-based service and the updated NCheck Bio Attendance 4.0 software.

NCheck Cloud Bio Attendance uses face recognition to enable users to check in and out from anywhere via the internet by taking selfies using mobile devices or a dedicated device for all users in the company.

In addition, NCheck Bio Attendance 4.0 software provides improved speed and usability as well as adds iris recognition to its fingerprint and face recognition capabilities for mobile or on-site time and attendance logging.

Neurotechnologys new biometric time and attendance tracking products create reports on their own and can export data to third party payroll applications.

A company can set up the NCheck Cloud time and attendance solution in just a few minutes, said Vaidas Didvalis, NCheck project manager for Neurotechnology. Users can check-in and check-out from anywhere using their own devices or they can use a dedicated device for a group of users. Iris recognition integration into the standalone NCheck Bio Attendance enables biometric check-in and check-out when fingerprints and face cannot be used a capability that hospitals and clinical research labs find particularly useful.

The new NCheck Cloud Bio Attendance cloud-based time and attendance service enables administrators to review attendance data, generate reports, add new users and complete other administrative functions via the Internet, eliminating the need to install or maintain software. The product allows up to five users to be registered using a free account.

NCheck Bio Attendance 4.0 provides an additional security layer with RFID card and barcode reader integration, which enables user identification through a combination of card scans and biometric verification.

The updated NCheck version includes a range of useful new reports, including productivity, absentee and late arrival.

Just as with its previous versions, NCheck Bio Attendance 4.0 is compatible with standard Windows PCs and off-the-shelf Android devices; supports a range of fingerprint scanners, device cameras and webcams; and includes GPS logging, database synchronization for remote workers, user grouping, shift support and attendance planning.

The updated version is available as a free upgrade to existing NCheck customers, while a free 30-day trial with full functionality is available for download and evaluation to new customers.

NCheck Cloud Bio Attendance and NCheck Bio Attendance 4.0 are now available at ncheck.net, the Neurotechnology website or from distributors worldwide. In addition, customers can order an Android tablet with NCheck Bio Attendance pre-installed.

Earlier this month, Neurotechnology released SentiVeillance 6.0 software development kit (SDK), which provides improved facial recognition using up to 10 surveillance, security and public safety cameras on a single computer, making it suitable for a wide range of surveillance applications.

comments

More:

Neurotechnology releases new biometric time and attendance products - Biometric Update

Stryker Co. (NYSE:SYK) declared a quarterly dividend on Wednesday, February 8th. Stockholders of record on Friday, March 31st will be given a dividend of 0.425 per share by the medical technology company on Friday, April 28th. This represents a $1.70 dividend on an annualized basis and a dividend yield of 1.28%. The ex-dividend date of this dividend is Wednesday, March 29th.

Stryker (NYSE:SYK) opened at 132.49 on Tuesday. The stock has a 50 day moving average price of $128.69 and a 200-day moving average price of $119.60. Stryker has a 1-year low of $104.61 and a 1-year high of $133.59. The stock has a market capitalization of $49.40 billion, a P/E ratio of 30.46 and a beta of 0.80.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 24th. The medical technology company reported $1.78 EPS for the quarter, topping analysts consensus estimates of $1.76 by $0.02. The company earned $3.20 billion during the quarter, compared to the consensus estimate of $3.15 billion. Stryker had a net margin of 14.54% and a return on equity of 23.86%. Strykers revenue for the quarter was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.56 earnings per share. Equities research analysts expect that Stryker will post $6.41 EPS for the current year.

SYK has been the subject of a number of recent research reports. Needham & Company LLC reissued a sell rating on shares of Stryker in a research note on Wednesday, January 25th. Wells Fargo & Co reissued an outperform rating and issued a $134.50 price objective on shares of Stryker in a research note on Saturday, January 28th. Jefferies Group LLC boosted their price objective on shares of Stryker from $120.00 to $132.00 and gave the stock a hold rating in a research note on Wednesday, January 25th. Edward Jones downgraded shares of Stryker from a buy rating to a hold rating in a research note on Thursday, January 5th. Finally, Zacks Investment Research raised shares of Stryker from a hold rating to a buy rating and set a $125.00 price objective for the company in a research note on Monday, December 5th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the companys stock. Stryker has a consensus rating of Buy and an average target price of $127.74.

In related news, VP Yin C. Becker sold 4,398 shares of the companys stock in a transaction dated Wednesday, February 15th. The shares were sold at an average price of $125.27, for a total transaction of $550,937.46. Following the completion of the transaction, the vice president now owns 12,541 shares in the company, valued at approximately $1,571,011.07. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Louise Francesconi sold 3,716 shares of the companys stock in a transaction dated Monday, January 30th. The stock was sold at an average price of $122.34, for a total transaction of $454,615.44. Following the transaction, the director now owns 20,242 shares of the companys stock, valued at approximately $2,476,406.28. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,968 shares of company stock worth $3,033,715. Corporate insiders own 7.80% of the companys stock.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Companys segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Go here to read the rest:

The Stryker Co. (SYK) to Issue Quarterly Dividend of $0.43 on April 28th - Petro Global News 24

A company can set up the NCheck Cloud time and attendance solution in just a few minutes.

Vilnius, Lithuania (PRWEB) March 28, 2017

Neurotechnology, a provider of high-precision biometric identification technologies, today announced the release of two biometric time and attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based service and the updatedNCheck Bio Attendance 4.0 software. NCheck Cloud Bio Attendance uses biometric face recognition to enable users to check in and out from anywhere via the internet by taking selfies using personal devices or a dedicated device for all users in the company. The latest NCheck Bio Attendance software provides enhanced speed and usability and adds iris recognition to its fingerprint and face recognition capabilities for mobile or on-site time and attendance logging. Both NCheck Cloud Bio Attendance and NCheck Bio Attendance 4.0 generate reports on their own and can export data to third party payroll applications.

A company can set up the NCheck Cloud time and attendance solution in just a few minutes, said Vaidas Didvalis, NCheck project manager for Neurotechnology. Users can check-in and check-out from anywhere using their own devices or they can use a dedicated device for a group of users. Iris recognition integration into the standalone NCheck Bio Attendance enables biometric check-in and check-out when fingerprints and face cannot be used a capability that hospitals and clinical research labs find particularly useful, Didvalis added.

With the new NCheck Cloud Bio Attendance cloud-based time and attendance service, all data is accessible via the internet, so administrators can review attendance data, generate reports, add new users and complete other administrative functions with no need to install or maintain software. Up to five users can be registered using a free account.

NCheck Bio Attendance 4.0 provides an extra measure of security with the addition of RFID card and barcode reader integration, which enables user identification through a combination of card scans and biometric verification. The addition of iris recognition is particularly useful in facilities where users cannot touch fingerprint sensors or where faces are often covered, such as hospitals and laboratories. The system administrator can choose which biometric option is preferred.

The latest NCheck version also includes an array of useful new reports, including productivity, absentee and late arrival. As in previous versions, NCheck Bio Attendance 4.0 works with standard Windows PCs and off-the-shelf Android devices; supports a wide range of fingerprint scanners, device cameras and webcams; and includes GPS logging, database synchronization for remote workers, user grouping, shift support and attendance planning among other capabilities.

As with all Neurotechnology products, the latest version of NCheck Bio Attendance is available as a free upgrade to existing NCheck customers. A 30-day trial with full functionality is available for download and evaluation.

NCheck Cloud Bio Attendance and NCheck Bio Attendance 4.0 are available at ncheck.net, through Neurotechnology at Neurotechnology.com or from distributors worldwide. Customers can also order an Android tablet with NCheck Bio Attendance pre-installed.

About Neurotechnology Neurotechnology is a provider of high-precision software and development products for biometric fingerprint, face, iris, palmprint and voice identification; object recognition; AI and robotics. Drawing from years of academic research in the fields of neuroinformatics, image processing and pattern recognition, Neurotechnology was founded in 1990 in Vilnius, Lithuania and released its first fingerprint identification system in 1991. Since that time the company has released more than 130 products and version upgrades for identification and verification of objects and personal identity. More than 3000 system integrators, security companies and hardware providers integrate Neurotechnology's algorithms into their products, with millions of customer installations worldwide.

Share article on social media or email:

View original post here:

Neurotechnology Releases New Cloud-based Biometric Time and Attendance Service, Updates NCheck Bio Attendance - PR Web (press release)

MANHATTAN (CN) Taking his federal defamation complaint against the New York Post to New York, a former house doctor for NBCs The Biggest Loser is represented now by the attorney who pinned Gawker for Hulk Hogan.

His new counsel aside, Robert Huizengas March 22 complaint in the Southern District of New York is otherwise on par with the case he filed nine months ago in Detroit.

Both suits name as defendants the New York Post and former Biggest Loser contestant Joelle Gwynn over a trio of articles that ran in May 2016.

The Posts first article on Dr. H as he is known to viewers was published on May 22; Biggest Loser drugged us so wed lose weight, its headline said.

On May 23, the Post ran Biggest Loser contestants demand NBC cancel show and a second story titled Biggest Loser rigged weigh-ins by forcing contestants to eat baking soda.

Gwynn is quoted in one of the articles as complaining that Huizenga and other Biggest Loser staffers pushed mysterious black and yellow stimulants onto contestants. People chastise Bill Cosby for allegedly offering meds to women, but its acceptable to do [sic] to fat people to make them lose weight, she had said. I feel like we got raped, too.

Black-and-yellow-colored Yellow Jacket pills contain ephedra extract, which is used to promote weight loss and boost energy. The Food and Drug Administration banned the pills in 2004. In the May 23 article, the Post reported that the show had tried to boost its ratings by pushing boring contestants to ingest baking soda so that they would retain water and gain weight and get booted off.

Huizenga maintains in his complaint, however, that he advocates for safe and effective weight loss methods, and has championed his aggressive non-surgical, non-drug approach to obesity on the past 17 seasons of the hit television series The Biggest Loser.

The safety and well-being of contestants on the show are of utmost importance to Dr. H, the complaint continues.

Saying that Post refused his demands for a correction, apology and retraction, Huizenga says the newspapers fictitious and outright libelous statements have interfered with his professional reputation. They also allegedly cost him business opportunities such as a production deal for a reality-television show based on Truthfulbrain.com, a program that uses MRI neurotechnology for lie detection.

Huizenga seeks punitive damages for defamation. He is represented by Charles Harder at Harder Mirell & Abrams. The Beverly Hills attorney famously won a $140 million verdict last year against Gawker, which the wrestler Hulk Hogan had sued for posting clips of his sex tape.

Representatives from the New York Post did not immediately respond to request for comment.

View original post here:

'Biggest Loser' Doctor Now Repped by Hulk's Winner - Courthouse News Service

Chaffey Breeze

Stryker Co. (SYK) to Issue Quarterly Dividend of $0.43 on April 28th Chaffey Breeze The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company's segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. and more »

Continued here:

Stryker Co. (SYK) to Issue Quarterly Dividend of $0.43 on April 28th - Chaffey Breeze

Three days before the AIPAC Policy Conference commences, lawmakers in the Senate and House introduced bipartisan resolutions on Wednesday to strengthen US economic cooperation with Israel. Representatives Ted Lieu (D-CA) and Ted Poe (R-TX) are leading the House version with Senators David Perdue (R-GA), Chris Coons (D-DE), Cory Gardner (R-CO), and Jon Tester (D-MT) behind the Senate bill. The US-Israel joint research institutions are collaborating on life-changing medical breakthroughs, and our technology sectors are fueling ground-breaking innovation, Lieu said.

This post originally appeared at JewishInsider.com

AIPAC, J Street, AJC, the Jewish Federations of North America, and US Chamber of Commerce are all endorsing the bipartisan effort. The resolutions encourage the Trump administration to support new agreements with Israel in the energy, water, neurotechnology and cyber security sectors.

With over 15,000 attendees expected for the AIPAC Policy Conference next week, lawmakers are rushing to introduce bills attractive to the pro-Israel community. After intense deliberations with Senators Ben Cardin (D-MD) and Bob Menendez (D-NJ) on a bipartisan Iran sanctions bill, Chairman of the Senate Foreign Relations Committee Bob Corker (R-TN) told Jewish Insider on Wednesday that Were down to just a couple of paragraphs and hopefully we will be able to complete discussions today. A previous area of contention among some Democrats is whether any new sanctions against Tehran would be interpreted as an attack on the nuclear agreement reached by the Obama Administration. Democratic Senator Chris Coons (D-DE) noted, however, that he would back new sanctions targeting Iran.

The Delaware lawmaker told Jewish Insider, Iran hasnt in any way moderated its behavior with regards to terrorism. Irans bad behavior with regards to human rights violations and ballistic missile launches has not only not moderated, if anything its worsened, since the JCPOA. Its important that we work to find a path a forward for a strong bipartisan bill that responds to the concerns.

Original post:

Congress introducing legislation ahead of AIPAC week Jewish ... - Jewish Journal

WASHINGTON, D.C. U.S. Sens. David Perdue, R-Ga.; Chris Coons, D-Del.; Cory Gardner, R-Colo., and Jon Tester, D-Mont., introduced bipartisan legislation Wednesday to recognize the accomplishments of the U.S.-Israel economic partnership and support new agreements for collaboration across a variety of sectors within the technology sphere.

Since the signing of the U.S.-Israel Free Trade Agreement, Israel has become one of the countrys largest economic collaborators in the Middle East and North Africa. Individual states are partnering with Israel to on life-changing medical breakthroughs and clean energy technology.

The kawmakers say the legislation is aimed at supporting and improving those partnerships.

Israel is a hub for innovation, and our strong alliance has paved the way for great economic opportunities, Perdue said. We will continue working with Prime Minister Netanyahu to explore new areas for collaboration across the economic spectrum.

I am proud to cosponsor a resolution that commemorates the strong economic ties between the United States and Israel and highlights opportunities for increased partnerships in fields such as agriculture, cybersecurity, and medicine, Coons added. I continue to be impressed with the entrepreneurial spirit of the Israeli people and will work with my colleagues to counter the economic isolation of Israel.

The other bill sp0nsors offered similar praise for the U.S.-Israeli partnership.

The U.S.-Israel alliance not only plays an important role to ensure peace and stability across the globe, but also serves both countries economic interests, Gardner said. As the only democracy in the Middle East, Israel highlights the benefits of a free society. Strong economic ties between our two nations have led to a partnership that both countries can be proud of, and as we look toward the future, we must continue to find ways we can work together to develop new technologies that will change the world.

The senators were joined by U.S. Sens. Susan Collins, R-Maine; Ted Cruz, R-Texas; Johnny Isakson, R-Ga.; Tim Kaine, D-Va.; Gary Peters, D-Mich., and Marco Rubio, R-Fla., in introducing Senate Resolution 90, which seeks to affirm the robustness of the economic relationship; recognize that science and technology innovation present new frontiers for economic cooperation; encourage the administration to expand and regularize existing forums of economic dialogue with Israel; and support the exploration of new agreements, including in the fields of energy, water, agriculture, medicine, neurotechnology and cybersecurity.

U.S. Reps. Ted Lieu, D-Calif., and Ted Poe, R-Texas, introduced companion legislation to the Senate resolution in the U.S. House of Representatives.

Success! An email has been sent with a link to confirm list signup.

Error! There was an error processing your request.

Get Breaking News alerts from the Albany Herald delivered to your email.

Get the Local News headlines from the Albany Herald delivered daily to your email.

Get the Sports headlines from the Albany Herald delivered daily to your email.

See more here:

Senate resolution supports economic collaborations with Israel - The Albany Herald

March 22, 2017-

Neurotechnology has released SentiVeillance 6.0 software development kit (SDK), which provides improved facial recognition using up to 10 surveillance, security and public safety cameras on a single computer, making it suitable for a wide range of surveillance applications.

According to a company statement, the new version uses deep neural-network-based facial detection and recognition algorithms to improve accuracy, and it utilizes a Graphing Processing Unit (GPU) for enhanced speed. In addition, users can more quickly and easily adjust the tradeoff between speed and accuracy as needed for different applications.

We developed SentiVeillance 6.0 as a self-adapting system based on deep neural networks that were trained on a larger quantity of data, said Ignas Namajunas, surveillance technologies research lead for Neurotechnology. This ensures better generalization for a variety of conditions. Additionally, by making use of the GPU processing capabilities, we were able to improve the processing speed significantly.

As with previous versions, the new SentiVeillance provides: real-time moving object detection; tracking and classification for pedestrians, vehicles and other predefined object classes based on size and speed of movement, and; area control that triggers events when people or objects enter, leave or stay in restricted areas.

comments

Follow this link:

Neurotechnology releases new SentiVeillance SDK - Biometric Update

Stryker Co. (NYSE:SYK) Leerink Swann lifted their FY2017 earnings per share estimates for shares of Stryker in a report issued on Monday. Leerink Swann analyst R. Newitter now anticipates that the firm will post earnings per share of $6.40 for the year, up from their previous forecast of $6.39. Leerink Swann also issued estimates for Strykers FY2018 earnings at $7.14 EPS.

Several other brokerages have also weighed in on SYK. Needham & Company LLC reissued a sell rating on shares of Stryker in a report on Wednesday, January 25th. Wells Fargo & Co reissued an outperform rating and issued a $134.50 price objective on shares of Stryker in a report on Saturday, January 28th. Jefferies Group LLC lifted their price objective on Stryker from $120.00 to $132.00 and gave the stock a hold rating in a report on Wednesday, January 25th. Edward Jones lowered Stryker from a buy rating to a hold rating in a report on Thursday, January 5th. Finally, Zacks Investment Research raised Stryker from a hold rating to a buy rating and set a $125.00 price objective for the company in a report on Monday, December 5th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $127.74.

Stryker (NYSE:SYK) opened at 132.38 on Wednesday. Stryker has a 1-year low of $104.34 and a 1-year high of $133.59. The stock has a 50 day moving average price of $127.53 and a 200 day moving average price of $119.14. The firm has a market cap of $49.36 billion, a P/E ratio of 30.43 and a beta of 0.80.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 24th. The medical technology company reported $1.78 earnings per share (EPS) for the quarter, beating the Thomson Reuters consensus estimate of $1.76 by $0.02. Stryker had a return on equity of 23.86% and a net margin of 14.54%. The company earned $3.20 billion during the quarter, compared to the consensus estimate of $3.15 billion. During the same quarter in the prior year, the firm posted $1.56 earnings per share. The firms revenue was up 16.3% compared to the same quarter last year.

A number of hedge funds have recently added to or reduced their stakes in the company. Capital Research Global Investors increased its stake in Stryker by 1.7% in the third quarter. Capital Research Global Investors now owns 33,537,131 shares of the medical technology companys stock worth $3,904,057,000 after buying an additional 556,349 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Stryker by 6.2% in the third quarter. Price T Rowe Associates Inc. MD now owns 17,503,094 shares of the medical technology companys stock worth $2,037,535,000 after buying an additional 1,022,233 shares during the last quarter. State Street Corp increased its stake in Stryker by 3.1% in the fourth quarter. State Street Corp now owns 13,774,848 shares of the medical technology companys stock worth $1,650,599,000 after buying an additional 419,118 shares during the last quarter. Franklin Resources Inc. increased its stake in Stryker by 2.2% in the fourth quarter. Franklin Resources Inc. now owns 12,270,194 shares of the medical technology companys stock worth $1,470,104,000 after buying an additional 265,300 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. increased its stake in Stryker by 1.1% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 8,620,753 shares of the medical technology companys stock worth $1,003,542,000 after buying an additional 95,303 shares during the last quarter. Institutional investors own 75.29% of the companys stock.

In other news, Director Louise Francesconi sold 3,716 shares of Stryker stock in a transaction dated Monday, January 30th. The stock was sold at an average price of $122.34, for a total transaction of $454,615.44. Following the completion of the sale, the director now owns 20,242 shares in the company, valued at approximately $2,476,406.28. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Yin C. Becker sold 11,660 shares of Stryker stock in a transaction dated Wednesday, January 4th. The shares were sold at an average price of $120.22, for a total value of $1,401,765.20. Following the sale, the vice president now owns 28,599 shares of the companys stock, valued at approximately $3,438,171.78. The disclosure for this sale can be found here. In the last quarter, insiders have sold 42,968 shares of company stock valued at $5,202,715. Corporate insiders own 7.80% of the companys stock.

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 28th. Stockholders of record on Friday, March 31st will be given a dividend of $0.425 per share. The ex-dividend date is Wednesday, March 29th. This represents a $1.70 dividend on an annualized basis and a dividend yield of 1.28%. Strykers dividend payout ratio (DPR) is presently 39.08%.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Companys segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

More:

The FY2017 EPS Estimates for Stryker Co. (SYK) Increased by Leerink Swann - Petro Global News 24